Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ELMDNASDAQ:GUTSNYSE:NVRONASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELMDElectromed$23.58-2.4%$28.19$13.74▼$35.56$201.77M0.4166,841 shs71,588 shsGUTSFractyl Health$1.14-1.7%$1.47$1.10▼$7.89$55.77M0.3289,326 shs337,768 shsNVRONevro$5.85+0.1%$5.64$3.17▼$13.84$224.32M0.81736,477 shs753,602 shsRCELAVITA Medical$7.51-3.8%$9.06$7.44▼$15.66$204.76M1.6188,865 shs366,322 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELMDElectromed-2.36%-0.25%-9.48%-23.17%+52.82%GUTSFractyl Health-1.72%-9.52%-24.00%-48.18%-84.49%NVRONevro+0.10%+0.02%+1.94%+57.57%-55.19%RCELAVITA Medical-3.84%-18.55%-14.27%-43.28%-50.40%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELMDElectromed1.091 of 5 stars2.00.00.00.03.42.50.0GUTSFractyl Health1.3847 of 5 stars3.52.00.00.00.61.70.0NVRONevro1.0082 of 5 stars1.05.00.00.01.91.70.6RCELAVITA Medical1.5894 of 5 stars3.30.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELMDElectromed 4.00Strong Buy$38.0061.15% UpsideGUTSFractyl Health 3.00Buy$10.00777.19% UpsideNVRONevro 1.92Reduce$6.439.90% UpsideRCELAVITA Medical 2.60Moderate Buy$17.25129.69% UpsideCurrent Analyst Ratings BreakdownLatest GUTS, NVRO, RCEL, and ELMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.002/20/2025ELMDElectromedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$38.002/20/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $22.002/19/2025ELMDElectromedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/14/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.002/10/2025NVRONevroJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Hold$4.50 ➝ $5.852/7/2025NVRONevroCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$4.00 ➝ $5.852/7/2025NVRONevroPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$6.00 ➝ $5.852/3/2025GUTSFractyl HealthMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$18.00 ➝ $10.001/8/2025RCELAVITA MedicalLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $14.001/8/2025RCELAVITA MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELMDElectromed$59.63M3.38$0.57 per share41.36$5.10 per share4.62GUTSFractyl Health$93K599.66N/AN/AN/A∞NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72RCELAVITA Medical$64.25M3.06N/AN/A$0.17 per share44.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELMDElectromed$5.15M$0.7531.44∞N/A11.34%15.71%13.37%N/AGUTSFractyl Health-$77.09M-$1.53N/AN/AN/A-64,849.48%N/A-57.21%4/7/2025 (Estimated)NVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%5/6/2025 (Estimated)RCELAVITA Medical-$61.85M-$2.39N/AN/AN/A-96.26%-337.91%-71.50%5/12/2025 (Estimated)Latest GUTS, NVRO, RCEL, and ELMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/4/2025Q4 2024NVRONevro-$0.79-$0.64+$0.15-$1.41$102.61 million$105.55 million3/3/2025Q4 2024GUTSFractyl Health-$0.44-$0.52-$0.08-$0.52N/AN/A2/13/2025Q4 2024RCELAVITA Medical-$0.30-$0.44-$0.14-$0.44$18.40 million$18.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELMDElectromedN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELMDElectromedN/A5.104.74GUTSFractyl Health0.605.585.57NVRONevro0.675.023.76RCELAVITA Medical9.392.832.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELMDElectromed40.82%GUTSFractyl HealthN/ANVRONevro95.52%RCELAVITA Medical27.66%Insider OwnershipCompanyInsider OwnershipELMDElectromed14.00%GUTSFractyl HealthN/ANVRONevro3.20%RCELAVITA Medical1.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELMDElectromed1608.56 million7.36 millionOptionableGUTSFractyl Health10248.92 millionN/AN/ANVRONevro1,21538.37 million36.27 millionOptionableRCELAVITA Medical13026.22 million25.74 millionOptionableGUTS, NVRO, RCEL, and ELMD HeadlinesRecent News About These CompaniesAvita Medical announces U.S. commercial launch of CohealyxApril 4 at 4:51 AM | msn.comAVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market OpportunityApril 3 at 4:03 PM | globenewswire.comAVITA Medical, Inc. (NASDAQ:RCEL) Sees Large Growth in Short InterestApril 1 at 12:45 PM | marketbeat.comAVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdlesMarch 21, 2025 | uk.investing.comAVITA Medical (NASDAQ:RCEL) Earns Buy Rating from D. Boral CapitalMarch 19, 2025 | marketbeat.com4RCEL : What Analysts Are Saying About AVITA Medical StockMarch 18, 2025 | benzinga.comAvita Medical amends PermeaDerm distribution agreement with Stedical ScientificMarch 17, 2025 | markets.businessinsider.comAvita Medical Boosts Production with New AgreementMarch 17, 2025 | tipranks.comAVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical ScientificMarch 17, 2025 | globenewswire.comDoes Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?March 13, 2025 | msn.comAvita Medical management to meet with Lake StreetFebruary 27, 2025 | markets.businessinsider.comAVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care ConferenceFebruary 26, 2025 | globenewswire.comAvita Medical price target lowered to $22 from $25 at D. Boral CapitalFebruary 20, 2025 | markets.businessinsider.comAVITA Medical, Inc. (RCEL): A Bull Case TheoryFebruary 20, 2025 | insidermonkey.comWall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should KnowFebruary 20, 2025 | zacks.comDavid D. O'toole Buys 1,000 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) StockFebruary 20, 2025 | insidertrades.comAfter Sales Rebound In January, AVITA Is Set Up For A Monster YearFebruary 18, 2025 | seekingalpha.comAvita Medical price target lowered to $11 from $12 at Piper SandlerFebruary 15, 2025 | markets.businessinsider.comAVITA Medical to Host Investor Webinar BriefingFebruary 14, 2025 | globenewswire.comAVITA Medical, Inc. (RCEL) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comAVITA Medical Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGUTS, NVRO, RCEL, and ELMD Company DescriptionsElectromed NYSE:ELMD$23.58 -0.57 (-2.36%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$21.58 -2.00 (-8.48%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Fractyl Health NASDAQ:GUTS$1.14 -0.02 (-1.72%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.14 +0.01 (+0.44%) As of 04/3/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025 07:56 PM EasternExtended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.AVITA Medical NASDAQ:RCEL$7.51 -0.30 (-3.84%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$7.76 +0.25 (+3.26%) As of 04/3/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
